Sorin Group and Greatbatch Announce Collaborative Agreement with Leverage Greatbatch's MRI Technology for Sorin Group CRM Devices
02 September 2008
The Sorin Group and Greatbatch announced today the execution of a letter of intent that will leverage Greatbatch’s Em-able™ technology in the Sorin Group’s future cardiac rhythm management (CRM) systems.
Catherine Picard, Vice President of research and development at Sorin Group said, “We are very excited by the opportunity to leverage Greatbatch’s eM-able™ technology to accelerate our MRI program to deliver MRI conditional systems to patients and physicians worldwide in the shortest possible time.”
Many patients implanted with a pacemaker or a defibrillator (ICD) cannot take advantage of an MRI scan, because energy from this life-saving technology can change how a device controls the heart, damages the device or injuries the heart tissue surrounding it.
MRI conditional approved devices are critical to allow patients with active implantable medical devices (AMIDs) to safely have an MRI for diagnostic evaluation.
“As we see more patients and receive AIMD’s the need for MRI conditional devices will continue to grow, said Mauricio Arellano, senior vice president of Greatbatch’s CRM and neuro modulation business. “This potential partnership with Sorin Group would meet that demand by securing our technology in their next generation devices.”
John Farrell, vice president of Greatbatch’s therapy delivery business, added, “There has been extensive research and technology development on eM-able™, and we are excited to get moving on our first commercialization program that will bring the technology to market, improving patient safety.”
